Fingolimod (FTY720) Hinders Interferon-γ-Mediated Fibrotic Scar Formation and Facilitates Neurological Recovery after Spinal Cord Injury

Following spinal cord injury (SCI), fibrotic scar inhibits axon regeneration and impairs neurological function recovery. It has been reported that T cell-derived interferon (IFN)-? plays a pivotal role in promoting fibrotic scarring in neurodegenerative disease. However, the role of IFN-? in fibrotic scar formation after SCI has not been declared. In this study, a spinal cord crush injury mouse was established. Western blot and immunofluorescence showed that IFN-? was surrounded by fibroblasts at 3, 7, 14, and 28 days post-injury. Moreover, IFN-? is mainly secreted by T cells after SCI. Further, in situ injection of IFN-? into the normal spinal cord resulted in fibrotic scar formation and inflammation response at 7 days post-injection. After SCI, the intraperitoneal injection of fingolimod (FTY720), a sphingosine-1-phosphate receptor 1 (S1PR1) modulator and W146, an S1PR1 antagonist, significantly reduced T cell infiltration, attenuating fibrotic scarring via inhibiting IFN-?/IFN-?R pathway, while in situ injection of IFN-? diminished the effect of FTY720 on reducing fibrotic scarring. FTY720 treatment inhibited inflammation, decreased lesion size, and promoted neuroprotection and neurological recovery after SCI. These findings demonstrate that the inhibition of T cell-derived IFN-? by FTY720 suppressed fibrotic scarring and contributed to neurological recovery after SCI.